TOP TEN perturbations for 38423_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38423_at
Selected probe(set): 212697_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38423_at (212697_at) across 6674 perturbations tested by GENEVESTIGATOR:
R547 study 1 (24h) / vehicle (DMSO) treated DU145 cell sample
Relative Expression (log2-ratio):-3.8225327Number of Samples:2 / 4
| Experimental | R547 study 1 (24h) |
| Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 24 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:--- | |
| Control | vehicle (DMSO) treated DU145 cell sample |
| Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 24 hours. |
stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Relative Expression (log2-ratio):2.7970686Number of Samples:3 / 4
| Experimental | stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast) |
| Proerythroblast differentiated from IRF6 (interferon regulatory factor 6) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF6 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. | |
| Control | stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast) |
| Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. |
kidney transplantation study 16 (2 week) / normal natural killer cell (CD56+) sample
Relative Expression (log2-ratio):-2.7023907Number of Samples:3 / 3
| Experimental | kidney transplantation study 16 (2 week) |
| CD56+ natural killer cell samples derived from kidney transplant patients 2 weeks post-transplantation. Samples were collected 2 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH). | |
| Control | normal natural killer cell (CD56+) sample |
| CD56+ natural killer cell samples derived from healthy control subjects. |
stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Relative Expression (log2-ratio):2.2247086Number of Samples:3 / 4
| Experimental | stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast) |
| Proerythroblast differentiated from IRF2 (interferon regulatory factor 2) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF2 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. | |
| Control | stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast) |
| Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. |
F. tularensis study 1 (tularensis Schu S4) / uninfected peripheral blood monocyte sample
Relative Expression (log2-ratio):-1.9717665Number of Samples:4 / 6
| Experimental | F. tularensis study 1 (tularensis Schu S4) |
| Peripheral blood monocytes infected with the Schu S4 isolate of Francisella tularensis (100 MOI) for 24 hours. | |
| Control | uninfected peripheral blood monocyte sample |
| Peripheral blood monocytes uninfected. |
acesulfame K study 1 (24h) / vehicle (DMSO) treated HepG2 cell sample
Relative Expression (log2-ratio):-1.9458561Number of Samples:3 / 7
| Experimental | acesulfame K study 1 (24h) |
| HepG2 cells exposed to 2mM acesulfame K in DMSO solvent for 24 hours. ATC code:--- | |
| Control | vehicle (DMSO) treated HepG2 cell sample |
| HepG2 cells exposed to DMSO solvent for 24 hours. |
paracetamol (acetaminophen) study 11 (24h) / vehicle (PBS) treated HepG2 cell sample
Relative Expression (log2-ratio):1.8827896Number of Samples:3 / 3
| Experimental | paracetamol (acetaminophen) study 11 (24h) |
| HepG2 cells exposed to 100μM acetaminophen (paracetamol) in PBS solvent for 24 hours. ATC code: | |
| Control | vehicle (PBS) treated HepG2 cell sample |
| HepG2 cells exposed to 0.5% PBS solvent for 24 hours. |
T-cell activation study 1 / quiescent CD4+ T-cell sample
Relative Expression (log2-ratio):-1.8770084Number of Samples:2 / 2
| Experimental | T-cell activation study 1 |
| CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 1 day. | |
| Control | quiescent CD4+ T-cell sample |
| Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors. |
diclofenac study 7 (24h) / vehicle (PBS) treated HepG2 cell sample
Relative Expression (log2-ratio):1.8369598Number of Samples:3 / 3
| Experimental | diclofenac study 7 (24h) |
| HepG2 cells exposed to 100μM diclofenac in PBS solvent for 24 hours. ATC code:, , | |
| Control | vehicle (PBS) treated HepG2 cell sample |
| HepG2 cells exposed to 0.5% PBS solvent for 24 hours. |
2-chloroethanol study 1 (24h) / vehicle (DMSO) treated HepG2 cell sample
Relative Expression (log2-ratio):-1.7861156Number of Samples:3 / 7
| Experimental | 2-chloroethanol study 1 (24h) |
| HepG2 cells exposed to 2mM 2-chloroethanol in DMSO solvent for 24 hours. ATC code:--- | |
| Control | vehicle (DMSO) treated HepG2 cell sample |
| HepG2 cells exposed to DMSO solvent for 24 hours. |